Summit Creek Advisors LLC Purchases Shares of 120,354 Artivion, Inc. $AORT

Summit Creek Advisors LLC purchased a new position in shares of Artivion, Inc. (NYSE:AORT) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 120,354 shares of the company’s stock, valued at approximately $2,704,000.

Other large investors also recently made changes to their positions in the company. Verition Fund Management LLC grew its stake in shares of Artivion by 1.6% in the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock valued at $716,000 after buying an additional 274 shares in the last quarter. Entropy Technologies LP raised its position in Artivion by 6.0% during the fourth quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock worth $251,000 after acquiring an additional 310 shares in the last quarter. Rockefeller Capital Management L.P. raised its position in Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after acquiring an additional 399 shares in the last quarter. Arizona State Retirement System lifted its stake in Artivion by 4.6% in the fourth quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock valued at $512,000 after acquiring an additional 494 shares during the last quarter. Finally, Amundi lifted its stake in Artivion by 7.5% in the first quarter. Amundi now owns 7,186 shares of the company’s stock valued at $263,000 after acquiring an additional 501 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Canaccord Genuity Group lifted their price objective on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings downgraded shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 target price on shares of Artivion in a research note on Monday, July 20th. Citizens Jmp reduced their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Finally, Citigroup reissued a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.83.

Artivion Trading Up 1.6%

Shares of Artivion stock opened at $28.78 on Wednesday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The business has a fifty day simple moving average of $24.60 and a two-hundred day simple moving average of $30.33. Artivion, Inc. has a 1 year low of $19.16 and a 1 year high of $48.25. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of -411.08 and a beta of 1.24.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The firm had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. Research analysts forecast that Artivion, Inc. will post 0.45 EPS for the current year.

Insider Activity

In other Artivion news, SVP Jean F. Holloway sold 977 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president directly owned 184,118 shares of the company’s stock, valued at $5,245,521.82. This represents a 0.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Andrew M. Green sold 44,001 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the sale, the senior vice president owned 60,259 shares of the company’s stock, valued at $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.